Become A Featured Company

Medical Marijuana Inc.’s RSHO™ Approved in Brazil for Autism

Ryan Allway

March 2nd, 2017

News, Top News

Autism is the fastest growing developmental disability in the world, affecting roughly 1% of the global population and 1-in-68 U.S. children. Emerging research suggests that cannabinoids like cannabidiol (CBD) could be beneficial in alleviating the symptoms of the disease, which has led some countries to begin importing the substance as a treatment option for citizens. This has created opportunities for public companies and investors involved in the space.

In this article, we will take a look at Medical Marijuana Inc.’s (OTC Pink: MJNA) recent approval for export into Brazil for the treatment of autism spectrum disorders.

CBD’s Potential to Treat Autism

Autism Spectrum Disorder affects roughly one in 68 children, according to the Centers for Disease Control, or roughly 1% of the world population. Between 2000 and 2010, the prevalence of autism in U.S. children has risen 119.4%, making it the fastest growing developmental disability. Services to support these individual cost the United States between $236 billion to $262 billion each year, according to a study published in JAMA.

Emerging research suggests that cannabinoids could be beneficial in the treatment of autism. In 2013, researchers discovered that mutations found in individuals with autism block the action of endocannabinoids, which could point to potential treatment strategies. Targeting components of the endocannabinoid signaling system may help reverse autism symptoms. Dr. Lester Grinspoon, MD, reported similar anecdotal evidence in a 2010 article in O’Shaughnessy’s.

Medical Marijuana Inc.’s Real Scientific Hemp Oil – or RSHO™ – is a natural, full-spectrum cannabidiol (CBD) oil extracted from hemp plants grown in Northern Europe. The non-GMO hemp is cultivated without the use of herbicides, pesticides, or chemical fertilizers and the resulting CBD oil passes all federal requirements for open importation into the United States, as well as strict European Union regulations governing exports.

HempMeds Brasil Secures Rights

Medical Marijuana Inc. recently announced that its HempMeds Brasil subsidiary secured approval for a prescription for RSHO to treat a patient with autism spectrum disorder. The move follows earlier approvals for the treatment of multiple sclerosis and Alzheimer’s disease, but marks the first time that Brazil’s National Health Surveillance Agency (ANVISA) has granted a prescription of the company’s RSHO™ for autism.

“We commend the Brazilian government for its compassionate approach to cannabis and for recognizing the need for alternative treatments to treat medical conditions for which there are currently no cure,” said Medical Marijuana Inc. CEO Dr. Stuart Titus. “We hope that this most recent decision by ANVISA will bring light to additional families in Brazil who have children with autism that could benefit from access to our hemp oil.”

Mexican neurosurgeon Dr. Saul Garza also indicated that he is enrolling patients for a study on the effects of CBD on autism. Earlier, Dr. Garza concluded a study on Lennox-Gastaut epilepsy in Mexico with favorable results for the botanical CBD version that is allowed into Mexico (RSHO-X). These results will be published in the near future and presented at the International Epilepsy Congress in Barcelona, Spain on September 2-6, 2017.

Looking Ahead

Medical Marijuana Inc. (OTC Pink: MJNA) has made tremendous progress in exporting its RSHO product lines around the world. With these approvals in place, the company can begin generating early-stage revenue along with valuable clinical data that it can use to support pharmaceutical-level development over the coming quarters. Investors may want to keep an eye on the stock given these short-term and long-term catalysts.

With a $300 million market capitalization, investors gain exposure to not only the company’s RSHO products, but its investments in several other subsidiaries. These subsidiaries include HempMedsPX (100%), Wellness Managed Services (80%), Red Dice Holdings (100%), CanChew Biotechnologies (50%), Hempwire (50%), Kannaway (100%), HempVap (50%), and HempMeds Brasil (93.4%) with each subsidiary offering compelling opportunities.

For more information, visit the company’s website or CannabisFN’s company profile.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading